TY - JOUR
T1 - The use of hemodynamic and cerebral monitoring to study pharmacodynamics in neonates
AU - Smits, A.
AU - Thewissen, L.
AU - Dereymaeker, A.
AU - Dempsey, E.
AU - Caicedo, A.
AU - Naulaers, G.
N1 - Funding Information:
Prof. Dempsey is supported by a Science Foundation Ireland Research Centre Award (INFANT-12/RC/2272). The research is further facilitated by the agency for innovation by Science and Technology in Flanders (IWT) through the SAFEPEDRUG project (IWT/SBO 130033).
Publisher Copyright:
© 2017 Bentham Science Publishers.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Background: Drugs acting on the cardiovascular and central nervous system often display relatively fast clinical responses, which may differ in neonates compared to children and adults. Introduction of bedside monitoring tools might be of additional value in the pharmacodynamic (PD) assessment of such drugs in neonates. Methods: We aim to provide an overview of the frequently used monitoring tools to assess drug effects on the hemodynamic status as well as the cerebral circulation, oxygenation and cerebral metabolism in neonates. Results: The use of blood pressure measurements, heart rate variability, functional echocardiography, near-infrared spectroscopy and (amplitude-integrated) electroencephalography in neonates is discussed, as well as new parameters introduced by these tools. Based on the ‘brain circulation model’, the hemodynamic effects on the brain and their interplay are summarized. In this model, 3 processes (i.e. blood processes, vascular smooth muscle processes and tissue processes) and 3 mechanisms (i.e. autoregulation, blood flow metabolism coupling and cerebral oxygen balance) are distinguished, which all may be influenced by drug administration. Finally, propofol, sevoflurane, midazolam and inotropes are used as examples of which PD has been studied using the available hemodynamic and/or cerebral monitoring tools. Conclusion: The implementation of (non-)invasive monitoring tools to document hemodynamic and cerebral PD effects in neonates is of relevance both in a neonatal research and intensive clinical care setting. We highlight the need to integrate these tools in future PD research. Furthermore, besides short-term drug effects, long-term outcome of drug therapy in neonates also warrants further attention.
AB - Background: Drugs acting on the cardiovascular and central nervous system often display relatively fast clinical responses, which may differ in neonates compared to children and adults. Introduction of bedside monitoring tools might be of additional value in the pharmacodynamic (PD) assessment of such drugs in neonates. Methods: We aim to provide an overview of the frequently used monitoring tools to assess drug effects on the hemodynamic status as well as the cerebral circulation, oxygenation and cerebral metabolism in neonates. Results: The use of blood pressure measurements, heart rate variability, functional echocardiography, near-infrared spectroscopy and (amplitude-integrated) electroencephalography in neonates is discussed, as well as new parameters introduced by these tools. Based on the ‘brain circulation model’, the hemodynamic effects on the brain and their interplay are summarized. In this model, 3 processes (i.e. blood processes, vascular smooth muscle processes and tissue processes) and 3 mechanisms (i.e. autoregulation, blood flow metabolism coupling and cerebral oxygen balance) are distinguished, which all may be influenced by drug administration. Finally, propofol, sevoflurane, midazolam and inotropes are used as examples of which PD has been studied using the available hemodynamic and/or cerebral monitoring tools. Conclusion: The implementation of (non-)invasive monitoring tools to document hemodynamic and cerebral PD effects in neonates is of relevance both in a neonatal research and intensive clinical care setting. We highlight the need to integrate these tools in future PD research. Furthermore, besides short-term drug effects, long-term outcome of drug therapy in neonates also warrants further attention.
UR - http://www.scopus.com/inward/record.url?scp=85043323746&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043323746&partnerID=8YFLogxK
U2 - 10.2174/1381612823666170918124419
DO - 10.2174/1381612823666170918124419
M3 - Review article
C2 - 28925890
AN - SCOPUS:85043323746
SN - 1381-6128
VL - 23
SP - 5955
EP - 5963
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 38
ER -